Journal of Surgical Research
Volume 157, Issue 1 , Pages e63-e70 , November 2009

Oncolytic Gene Therapy Combined with Double Suicide Genes for Human Bile Duct Cancer in Nude Mouse Models

  • Yoh Kojima, M.D.

      Affiliations

    • Department of Organ Regulatory Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon City, Ehime, Japan
    • ,
  • Kazuo Honda, M.D.

      Affiliations

    • Department of Organ Regulatory Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon City, Ehime, Japan
    • Corresponding Author InformationTo whom correspondence and reprint requests should be addressed at Department of Organ Regulatory Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon City, Ehime, 791-0295, Japan.
    • ,
  • Hirofumi Hamada, M.D.

      Affiliations

    • Molecular Medicine Division, Biomedical Center, Sapporo Medical University School of Medicine, Sapporo, Hokkaido, Japan
    • ,
  • Nobuaki Kobayashi, M.D.

      Affiliations

    • Department of Organ Regulatory Surgery, Ehime University Graduate School of Medicine, Shitsukawa, Toon City, Ehime, Japan

Received 7 November 2008

References 

  1. Uehara T, Honda K, Hatano E, et al. Gene transfer to the rat biliary tract with the HVJ-cationic liposome method. J Hepatol. 1999;30:836
  2. Terao R, Honda K, Hatano E, et al. Suppression of proliferative cholangitis in a rat model with direct adenovirus-mediated retinoblastoma gene transfer to the biliary tract. Hepatology. 1998;28:605
  3. Kojima Y, Honda K, Kotegawa H, et al. Adenovirus-mediated p53 gene transfer to the bile duct by direct administration into the bile in a rat cholangitis model. J Sug Res. 2005;128:126
  4. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett. 2007;254:178
  5. Khan SA, Thomas HC, Tolodano MB, et al. p53 mutations in human cholangiocarcinoma: A review. Liver Int. 2005;25:704
  6. Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3:639
  7. Borrelli E, Heyman R, His M, et al. Targeting of an inducible toxic phenotype in animal cell. Proc Natl Acad Sci USA. 1988;85:7572
  8. Kanai F, Kawakami T, Hamada H, et al. Adenovirus-mediated transduction of Esherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res. 1998;58:1946
  9. Mani S, Sciortino D, Samuels B, et al. Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. Invest New Drugs. 1999;17:97
  10. Furuse J, Okusaka T, Funakoshi A, et al. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol. 2006;36:552
  11. Yonemoto N, Furuse J, Okusaka T, et al. A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Jpn J Clin Oncol. 2007;37:843
  12. Shimizu T, Shimada H, Ochiai T, et al. Enhanced growth suppression in esophageal carcinoma cells using adenovirus-mediated fusion gene transfer (uracil phosphoribosyl transferase and helpes simplex virus thymidine kinase). Cancer Gene Ther. 2001;8:512
  13. Schneider JF, Fisher F, Goding CR, et al. Mutational analysis of the adenovirus E1a gene: the role of transcriptional regulation in transformation. EMBO J. 1987;6:2053
  14. Takahashi M, Sato T, Sagawa T, et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther. 2002;5:627
  15. Sirica AE, Zhan Z, Lai GH, et al. A novel “patient-like” model of cholangiocarcinoma progression based on bile duct inoculation of tumorigenic rat cholangiocyte cell lines. Hepatology. 2008;47:1178
  16. Lie-A-Ling M, Bakker CT, Deurholt T, et al. Selection of tumor specific promoters for adenoviral gene therapy of cholangiocarcinoma. J Hepatol. 2006;44:126
  17. Tullo A, D'Erchia AM, Honda K, et al. New p53 mutation in hilar cholangiocarcinoma. Eur J Clin Invest. 2000;30:798
  18. Strum PD, Baas IO, Clement MJ, et al. Alterations of the p53 tumor-suppressor gene and K-ras oncogene in perihilar cholangiocarcinoma from a high-incidence area. Int J Cancer 9;78:695.

PII: S0022-4804(08)01575-8

doi: 10.1016/j.jss.2008.12.016

Journal of Surgical Research
Volume 157, Issue 1 , Pages e63-e70 , November 2009

Article Tools

* Image Usage & Resolution